FGFR3 INHIBITOR COMPOUNDS

The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or ca...

Full description

Saved in:
Bibliographic Details
Main Authors METCALF, Andrew Terrance, WALLS, Shane Michael, CONDROSKI, Kevin Ronald, DILGER, Andrew Karl, ABRAHAM, Adedoyin David, KERCHER, Timothy Scott, URKALAN, Kaveri Balan, HAZLITT, Robert Alan, BUME, Desta Doro
Format Patent
LanguageEnglish
French
Published 09.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer. La présente invention concerne des composés de formule : destinés à être utilisés dans le traitement de la sclérodermie généralisée, de la fibrose (par exemple, la fibrose pulmonaire), l'achondroplasie, la dysplasie thanatophore (par exemple, de type I), l'achondroplasie sévère avec un retard de développement et une acanthosis nigricans (SADDAN), le syndrome de Muenke ou le cancer.
AbstractList The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer. La présente invention concerne des composés de formule : destinés à être utilisés dans le traitement de la sclérodermie généralisée, de la fibrose (par exemple, la fibrose pulmonaire), l'achondroplasie, la dysplasie thanatophore (par exemple, de type I), l'achondroplasie sévère avec un retard de développement et une acanthosis nigricans (SADDAN), le syndrome de Muenke ou le cancer.
Author METCALF, Andrew Terrance
DILGER, Andrew Karl
WALLS, Shane Michael
URKALAN, Kaveri Balan
KERCHER, Timothy Scott
HAZLITT, Robert Alan
BUME, Desta Doro
CONDROSKI, Kevin Ronald
ABRAHAM, Adedoyin David
Author_xml – fullname: METCALF, Andrew Terrance
– fullname: WALLS, Shane Michael
– fullname: CONDROSKI, Kevin Ronald
– fullname: DILGER, Andrew Karl
– fullname: ABRAHAM, Adedoyin David
– fullname: KERCHER, Timothy Scott
– fullname: URKALAN, Kaveri Balan
– fullname: HAZLITT, Robert Alan
– fullname: BUME, Desta Doro
BookMark eNrjYmDJy89L5WSQdHN3CzJW8PTz8HTyDPEPUnD29w3wD_VzCeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRkaGFuYmJsaOhsbEqQIAZrUiqA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate COMPOSÉS INHIBITEURS DE FGFR3
ExternalDocumentID WO2022187443A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2022187443A13
IEDL.DBID EVB
IngestDate Fri Nov 01 05:39:17 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2022187443A13
Notes Application Number: WO2022US18644
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220909&DB=EPODOC&CC=WO&NR=2022187443A1
ParticipantIDs epo_espacenet_WO2022187443A1
PublicationCentury 2000
PublicationDate 20220909
PublicationDateYYYYMMDD 2022-09-09
PublicationDate_xml – month: 09
  year: 2022
  text: 20220909
  day: 09
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies ELI LILLY AND COMPANY
RelatedCompanies_xml – name: ELI LILLY AND COMPANY
Score 3.4185996
Snippet The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia,...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title FGFR3 INHIBITOR COMPOUNDS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220909&DB=EPODOC&locale=&CC=WO&NR=2022187443A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-J0SkHpW7G26dfDEJu2tkKbUjvd21jaCILM4Sr--15Dp3vaW5KDywdc7n7JfQDcoBrlxlwYGuEIV9tshBqfC0erCK9s607oQlYtSTM7npCnqTXtwcc6FkbmCf2RyRFRoiqU90be18v_R6xA-laubvk7Dn3eR-U4UDt0bBi6p3tq4I_DnAWMqpQiblOzQtLa8nPEfECstIOGtNPKQ_jit3Epy02lEh3Cbo78Fs0R9MRiAPt0XXttAHtp9-WNzU76VscwjB6jwlSSLE78pGSFQlmas0kWPJ_AdRSWNNZwjtnflmavbHNB5in0EeyLM1CEsN-s2kOtYQjikpq7rnC4WwvuoOHBjSGMtnE6306-gIO2K32kvBH0m69vcYlKteFX8ix-AV7kdtQ
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq2K1akDJLRg370MR8zLR5kFMtbfQTbYgSC024t93sqTaU2_LDsw-4NvZb3ceADdoRimZMSKpFOlqk41QojNmSKVKS127YzLjVUuiWA8m6tNUm3bgYx0Lw_OE_vDkiIioEvFe8_N6-f-I5XLfytUtfceuz3s_H7liy44JkS3ZEl175KWJmzii4yBvE-OMy5ryc6rygFxpBy_ZRoMH79Vu4lKWm0bFP4DdFPUt6kPosEUfes669lof9qL2yxubLfpWRzDwH_1MEcI4CO0wTzLBSaI0mcTuyzFc-17uBBKOUfwtqXhLNieknEAXyT47BYExfa5VFloNwlRTrahpMoOaFaMGXjwoGcBwm6az7eIr6AV5NC7GYfx8DvuNiPtLWUPo1l_f7AINbE0v-b78AhvIecc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=FGFR3+INHIBITOR+COMPOUNDS&rft.inventor=METCALF%2C+Andrew+Terrance&rft.inventor=WALLS%2C+Shane+Michael&rft.inventor=CONDROSKI%2C+Kevin+Ronald&rft.inventor=DILGER%2C+Andrew+Karl&rft.inventor=ABRAHAM%2C+Adedoyin+David&rft.inventor=KERCHER%2C+Timothy+Scott&rft.inventor=URKALAN%2C+Kaveri+Balan&rft.inventor=HAZLITT%2C+Robert+Alan&rft.inventor=BUME%2C+Desta+Doro&rft.date=2022-09-09&rft.externalDBID=A1&rft.externalDocID=WO2022187443A1